Thomas Modine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

“Lifetime management” is the catchphrase in a range of sessions at PCR London Valves tackling TAVI’s unanswered big questions.

Odds of a study coming to fruition are low

May 21, 2021 Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR. On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches—annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement—aimed at addressing this clinical niche. All three are manufactured by Edwards Lifesciences: Thirty-day data...

Photo Credit: Hannes Alessandrini) As MitraClip procedures continue to expand as an option for nonsurgical patients with functional or degenerative mitral regurgitation (MR), a new question will increasingly arise: what’s the best approach for treating patients whose clip procedures fail? Now, a small, retrospective, single-center study is trying to shed some light. As Hannes Alessandrini, MD (Asklepios Klinik St. Georg, Hamburg, Germany), and colleagues write in EuroIntervention this month, the best approach may depend on the source of mitral valve dysfunction in the first place. “There...